США - англійська - NLM (National Library of Medicine)

virtus pharmaceuticals - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 0.2 mg in 1 ml - contraindicated in people with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

США - англійська - NLM (National Library of Medicine)

dispensing solutions, inc. - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

США - англійська - NLM (National Library of Medicine)

physicians total care, inc. - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

США - англійська - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

США - англійська - NLM (National Library of Medicine)

golden state medical supply, inc. - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

США - англійська - NLM (National Library of Medicine)

st marys medical park pharmacy - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

США - англійська - NLM (National Library of Medicine)

proficient rx lp - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

США - англійська - NLM (National Library of Medicine)

american health packaging - doxercalciferol (unii: 3diz9lf5y9) (doxercalciferol - unii:3diz9lf5y9) - doxercalciferol 0.5 ug - dialysis patients doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. pre-dialysis patients doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with stage 3 or stage 4 chronic kidney disease. doxercalciferol should not be given to patients with a tendency towards hypercalcemia or current evidence of vitamin d toxicity.

США - англійська - NLM (National Library of Medicine)

amneal pharmaceuticals llc - doxercalciferol (unii: 3diz9lf5y9) (doxercalciferol - unii:3diz9lf5y9) - doxercalciferol 2 ug in 1 ml - - doxercalciferol injection is indicated for the treatment of secondary hyperparathyroidism in adult patients with ckd on dialysis. doxercalciferol is contraindicated in patients with: - hypercalcemia [see warnings and precautions (5.1)] - vitamin d toxicity [see warnings and precautions (5.1)] - known hypersensitivity to doxercalciferol or any of the inactive ingredients of doxercalciferol injection; serious hypersensitivity reactions including anaphylaxis and angioedema have been reported [see warnings and precautions (5.3), adverse reactions (6.2)]. risk summary the limited available data with doxercalciferol in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy [see clinical considerations] . in reproduction studies in rats and rabbits administered doxercalciferol during organogenesis at up to 20 mcg/kg/day and 0.1 mcg/kg/day, respectively (approximately 25 times (rats) and less than (rabbits) the maximum recommended human oral dose of 60 mcg/week based on mcg/m2 body surface area), no adverse developmental effects were observed [see data] . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk chronic kidney disease in pregnancy increases the risk for maternal hypertension and preeclampsia, miscarriage, preterm delivery polyhydramnios, stillbirth, and low-birth-weight infants. data animal data there were no adverse effects on fetal development when doxercalciferol was administered at doses up to 20 mcg/kg/day in pregnant rats or doses up to 0.1 mcg/kg/day in pregnant rabbits during the period of organogenesis. risk summary there is no information available on the presence of doxercalciferol in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. infants exposed to doxercalciferol through breast milk should be monitored for signs and symptoms of hypercalcemia [see clinical considerations] . the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for doxercalciferol and any potential adverse effects on the breastfed child from doxercalciferol or from the underlying maternal condition. clinical considerations infants exposed to doxercalciferol injection through breast milk should be monitored for signs and symptoms of hypercalcemia, including seizures, vomiting, constipation and weight loss. monitoring of serum calcium in the infant should be considered. safety and efficacy of doxercalciferol in pediatric patients have not been established. clinical studies of doxercalciferol did not include sufficient numbers of patients 65 years or over to determine whether they respond differently from younger subjects. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic or cardiac function, and of concomitant disease or other drug therapy. patients with hepatic impairment may not metabolize doxercalciferol appropriately. more frequent monitoring of intact pth, calcium, and phosphorus levels should be done in patients with hepatic impairment.

США - англійська - NLM (National Library of Medicine)

bionpharma inc. - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.